Connection

WILLEM OVERWIJK to Membrane Glycoproteins

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Membrane Glycoproteins.
Connection Strength

0.512
  1. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18; 198(4):569-80.
    View in: PubMed
    Score: 0.155
  2. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol. 2000; 20(6):433-50.
    View in: PubMed
    Score: 0.121
  3. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2982-7.
    View in: PubMed
    Score: 0.114
  4. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005 Mar 01; 174(5):2591-601.
    View in: PubMed
    Score: 0.043
  5. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998 Jul 20; 188(2):277-86.
    View in: PubMed
    Score: 0.027
  6. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997 Jan; 20(1):15-25.
    View in: PubMed
    Score: 0.025
  7. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75.
    View in: PubMed
    Score: 0.013
  8. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008 Jan; 31(1):1-6.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.